Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Compass Therapeutics Inc (CMPX)

Compass Therapeutics Inc (CMPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Compass Therapeutics Provides Corporate Update GlobeNewswire - Tue Jan 6, 7:00AM CST

The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody)...

CMPX : 5.71 (+0.18%)
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Jan 5, 3:30PM CST

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...

CMPX : 5.71 (+0.18%)
Compass Therapeutics Announces Key Leadership Appointments GlobeNewswire - Mon Jan 5, 7:00AM CST

BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...

CMPX : 5.71 (+0.18%)
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference GlobeNewswire - Wed Dec 17, 2025

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today...

CMPX : 5.71 (+0.18%)
Compass Therapeutics to Participate in Upcoming December Investor Events GlobeNewswire - Tue Nov 25, 2025

BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today...

CMPX : 5.71 (+0.18%)
Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Wed Nov 5, 2025

Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the...

CMPX : 5.71 (+0.18%)
Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire - Tue Nov 4, 2025

CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies. In vivo, CTX-10726 outperformed...

CMPX : 5.71 (+0.18%)
Compass Therapeutics to Participate in Upcoming November Investor Events GlobeNewswire - Mon Nov 3, 2025

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...

CMPX : 5.71 (+0.18%)
Compass Therapeutics to Participate in Upcoming September Investor Events GlobeNewswire - Tue Aug 26, 2025

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...

CMPX : 5.71 (+0.18%)
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering GlobeNewswire - Tue Aug 12, 2025

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based...

CMPX : 5.71 (+0.18%)

Barchart Exclusives

Trump’s Greenland Threats Scaring You Off? Buy This Dividend Stock as a Hedge Barchart - Tue Jan 20, 6:30PM CST
Trump's threats to seize Greenland have led to a selloff in risk assets while precious metals have rallied amid the flight to safe-haven assets. Agnico-Eagle Mines is a good dividend stock to buy amid the geopolitical turmoil. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot